1706438-18-7 Usage
Uses
Used in Pharmaceutical Industry:
(S)-6-methyl-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine is used as a potential pharmaceutical compound for its diverse biological activities. (S)-6-methyl-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine's heterocyclic nature and chirality make it a promising candidate for the development of new drugs with antimicrobial, antiviral, and anticancer properties.
Used in Organic Synthesis:
In the field of organic chemistry, (S)-6-methyl-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine is used as a valuable building block for the synthesis of more complex organic molecules. Its unique structure and chirality can be exploited to create novel compounds with specific applications in various industries, including pharmaceuticals, agrochemicals, and materials science.
Used in Research and Development:
(S)-6-methyl-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine is also utilized in research and development for the study of its chemical properties, reactivity, and potential interactions with other molecules. This knowledge can be applied to design and develop new drugs and materials with improved properties and functionalities.
Check Digit Verification of cas no
The CAS Registry Mumber 1706438-18-7 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,7,0,6,4,3 and 8 respectively; the second part has 2 digits, 1 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 1706438-18:
(9*1)+(8*7)+(7*0)+(6*6)+(5*4)+(4*3)+(3*8)+(2*1)+(1*8)=167
167 % 10 = 7
So 1706438-18-7 is a valid CAS Registry Number.
1706438-18-7Relevant academic research and scientific papers
SULFONIMIDAMIDE COMPOUNDS AS NLRP3 MODULATORS
-
Paragraph 0335; 0336, (2021/07/31)
Described herein are compounds of Formula (I), Formula (I-A), and Formula (I-B), solvates thereof, tautomers thereof, and pharmaceutically acceptable salts of the foregoing, Further described herein are methods of inhibiting NLRP3 using said compounds, and methods of and compositions useful in treating NLRP3-dependent disorders.
CHEMICAL COMPOUNDS AS INHIBITORS OF INTERLEUKIN-1 ACTIVITY
-
Paragraph 00698; 00699, (2018/08/12)
The present disclosure relates to novel sulfonylurea and sulfonyl thiourea compounds and related compounds and their use in treating a disease or condition responsive to modulation of cytokines such as IL-1β and IL-18, modulation of NLRP3 or inhibition of the activation of NLRP3 or related components of the inflammatory process.
